Literature DB >> 28233660

PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.

Ide Cremin1, Lyle McKinnon2, Joshua Kimani3, Peter Cherutich4, Gloria Gakii3, Festus Muriuki5, Katharine Kripke6, Robert Hecht7, Michael Kiragu8, Jennifer Smith9, Wes Hinsley9, Lawrence Gelmon3, Timothy B Hallett9.   

Abstract

BACKGROUND: The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP) could be used in Nairobi, Kenya.
METHODS: A mathematical model was developed to represent HIV transmission in specific key populations (female sex workers, male sex workers, and men who have sex with men [MSM]) and among the wider population of Nairobi. The scale-up of existing interventions (condom promotion, antiretroviral therapy, and male circumcision) for key populations and the wider population as have occurred in Nairobi is represented. The model includes a detailed representation of a PrEP intervention and is calibrated to prevalence and incidence estimates specific to key populations and the wider population.
FINDINGS: In the context of a declining epidemic overall but with a large sub-epidemic in MSM and male sex workers, an optimal prevention portfolio for Nairobi should focus on condom promotion for male sex workers and MSM in particular, followed by improved antiretroviral therapy retention, earlier antiretroviral therapy, and male circumcision as the budget allows. PrEP for male sex workers could enter an optimal portfolio at similar levels of spending to when earlier antiretroviral therapy is included; however, PrEP for MSM and female sex workers would be included only at much higher budgets. If PrEP for male sex workers cost as much as US$500, average annual spending on the interventions modelled would need to be less than $3·27 million for PrEP for male sex workers to be excluded from an optimal portfolio. Estimated costs per infection averted when providing PrEP to all female sex workers regardless of their risk of infection, and to high-risk female sex workers only, are $65 160 (95% credible interval [CrI] $43 520-$90 250) and $10 920 (95% CrI $4700-$51 560), respectively.
INTERPRETATION: PrEP could be a useful contribution to combination prevention, especially for under-served key populations in Nairobi. An ongoing demonstration project will provide important information regarding practical aspects of implementing PrEP for key populations in this setting. FUNDING: The Bill & Melinda Gates Foundation.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28233660     DOI: 10.1016/S2352-3018(17)30021-8

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  18 in total

1.  "The Drug Will Help Protect My Tomorrow": Perceptions of Integrating PrEP into HIV Prevention Behaviors Among Female Sex Workers in Lilongwe, Malawi.

Authors:  Jaclyn Shea; Agatha Bula; Wezzie Dunda; Mina C Hosseinipour; Carol E Golin; Irving F Hoffman; William C Miller; Vivian F Go; Thandie Lungu; Kathryn E Lancaster
Journal:  AIDS Educ Prev       Date:  2019-10

2.  HIV control strategies for sex worker-client contact networks.

Authors:  Nicola Mulberry; Alexander R Rutherford; Ralf W Wittenberg; Brian G Williams
Journal:  J R Soc Interface       Date:  2019-09-25       Impact factor: 4.118

3.  HIV prevention resources: time to move toward affordability.

Authors:  April D Kimmel; Denis Nash
Journal:  Lancet HIV       Date:  2017-02-21       Impact factor: 12.767

4.  A modeling framework to inform preexposure prophylaxis initiation and retention scale-up in the context of 'Getting to Zero' initiatives.

Authors:  Aditya S Khanna; John A Schneider; Nicholson Collier; Jonathan Ozik; Rodal Issema; Angela di Paola; Abigail Skwara; Arthi Ramachandran; Jeannette Webb; Russell Brewer; William Cunningham; Charles Hilliard; Santhoshini Ramani; Kayo Fujimoto; Nina Harawa
Journal:  AIDS       Date:  2019-10-01       Impact factor: 4.177

Review 5.  Lessons from a decade of voluntary medical male circumcision implementation and their application to HIV pre-exposure prophylaxis scale up.

Authors:  Jason B Reed; Rupa R Patel; Rachel Baggaley
Journal:  Int J STD AIDS       Date:  2018-08-16       Impact factor: 1.359

6.  Cost-effectiveness of HIV Prevention Interventions in Sub-Saharan Africa: A Systematic Review.

Authors:  Supriya Sarkar; Phaedra Corso; Shideh Ebrahim-Zadeh; Patricia Kim; Sana Charania; Kristin Wall
Journal:  EClinicalMedicine       Date:  2019-05-20

Review 7.  Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale-up: a synthesis of evidence from sub-Saharan Africa.

Authors:  Robyn Eakle; Peter Weatherburn; Adam Bourne
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

8.  HIV transmission and pre-exposure prophylaxis in a high risk MSM population: A simulation study of location-based selection of sexual partners.

Authors:  Olivier Robineau; Annie Velter; Francis Barin; Pierre-Yves Boelle
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

Review 9.  Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?

Authors:  Robyn Eakle; Francois Venter; Helen Rees
Journal:  Retrovirology       Date:  2018-04-02       Impact factor: 4.602

10.  Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.

Authors:  Chutima Suraratdecha; Robyn M Stuart; Chomnad Manopaiboon; Dylan Green; Cheewanan Lertpiriyasuwat; David P Wilson; Patcharaporn Pavaputanon; Prin Visavakum; Patama Monkongdee; Thana Khawcharoenporn; Phiphatthananon Tharee; Chonticha Kittinunvorakoon; Michael Martin
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.